Education
About Us
Working with TipRanks
Follow Us
Sigyn Therapeutics (SIGY)
OTHER OTC:SIGY
SIGY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.49 - $5.75
Previous CloseN/A
Volume87.00
Average Volume (3M)879.00
Market Cap
$4.43M
Enterprise ValueN/A
Total Cash (Recent Filing)$459.00
Total Debt (Recent Filing)$2.57M
Price to Earnings (P/E)―
Beta-0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding1,605,377
10 Day Avg. Volume460
30 Day Avg. Volume879
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sigyn Therapeutics News
SIGY FAQ
What was Sigyn Therapeutics’s price range in the past 12 months?
Sigyn Therapeutics lowest stock price was $2.49 and its highest was $5.75 in the past 12 months.
What is Sigyn Therapeutics’s market cap?
Sigyn Therapeutics’s market cap is $4.43M.
When is Sigyn Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sigyn Therapeutics’s earnings last quarter?
Currently, no data Available
Is Sigyn Therapeutics overvalued?
According to Wall Street analysts Sigyn Therapeutics’s price is currently Overvalued.
Does Sigyn Therapeutics pay dividends?
Sigyn Therapeutics does not currently pay dividends.
What is Sigyn Therapeutics’s EPS estimate?
Sigyn Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sigyn Therapeutics have?
Sigyn Therapeutics has 1,605,377 shares outstanding.
What happened to Sigyn Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sigyn Therapeutics?
Currently, no hedge funds are holding shares in SIGY
Company Description
Sigyn Therapeutics
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
Technical Analysis
Palatin Technologies
―
Evogene
―
MetaVia
―
TransCode Therapeutics
―
Silexion Therapeutics
―